<div class="welcome-screen" id="welcomeScreen">
    <div class="welcome-banner">
        <h1 id="welcome-title">Welcome to page on antibiotics!</h1>
        <p id="welcome-description">Explore all the various type, as well as stewardship.</p>
    </div>
    
    <div class="explanation-card">
        <h1>Introduction to Antibiotics: History and Fundamental Concepts</h1>
        
        <p>The discovery of antibiotics represents one of the most significant medical advancements in human history, fundamentally transforming our ability to treat bacterial infections. Before the antibiotic era, minor infections could prove fatal, and surgical procedures carried tremendous risk of postoperative infection. The term <b>antibiotic</b> originates from the Greek words "anti" (against) and "bios" (life), referring to substances produced by microorganisms that inhibit or kill other microorganisms.</p>
        
        <h2>Historical Milestones</h2>
        <p>The modern antibiotic era began in 1928 with Alexander Fleming's serendipitous discovery of penicillin from the mold <i>Penicillium notatum</i>. However, it wasn't until the 1940s that Howard Florey and Ernst Chain developed methods for mass production, enabling widespread clinical use during World War II. The period from 1940-1960 is often called the "golden age of antibiotics," witnessing the discovery of most major antibiotic classes we use today.</p>
        
        <h2>Fundamental Concepts</h2>
        <p>Antibiotics can be classified based on their <b>mechanism of action</b>:</p>
        <ol>
            <li><b>Cell wall synthesis inhibitors</b> (e.g., β-lactams, glycopeptides)</li>
            <li><b>Protein synthesis inhibitors</b> (e.g., aminoglycosides, tetracyclines, macrolides)</li>
            <li><b>Nucleic acid synthesis inhibitors</b> (e.g., quinolones, rifamycins)</li>
            <li><b>Metabolic pathway inhibitors</b> (e.g., sulfonamides, trimethoprim)</li>
            <li><b>Membrane disruptors</b> (e.g., polymyxins, daptomycin)</li>
        </ol>
        
        <p>Understanding these mechanisms is crucial for selecting appropriate therapy, predicting side effects, and combating resistance. Antibiotics may be <b>bactericidal</b> (killing bacteria) or <b>bacteriostatic</b> (inhibiting growth), though this distinction can depend on concentration and bacterial species.</p>
        
        <div class="mnemonic">
            <b>Mnemonic: "Some Critters Make Pretty Nutritious Meals"</b> for antibiotic mechanisms:<br>
            <b>S</b>ynthesis inhibitors (cell wall)<br>
            <b>C</b>ytoplasmic membrane disruptors<br>
            <b>M</b>etabolic pathway inhibitors<br>
            <b>P</b>rotein synthesis inhibitors<br>
            <b>N</b>ucleic acid synthesis inhibitors
        </div>
    </div>

    <div class="question-card">
        <h1>Question 1</h1>
        <p>Which of the following statements about the history of antibiotics is correct?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Penicillin was first synthesized in a laboratory in 1942</li>
            <li data-answer="correct">The therapeutic potential of penicillin was demonstrated during World War II</li>
            <li data-answer="wrong">Alexander Fleming immediately recognized penicillin's clinical potential when he discovered it</li>
            <li data-answer="wrong">The first antibiotic used clinically was streptomycin</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 2</h1>
        <p>Which antibiotic class works by inhibiting cell wall synthesis?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Tetracyclines</li>
            <li data-answer="correct">Cephalosporins</li>
            <li data-answer="wrong">Aminoglycosides</li>
            <li data-answer="wrong">Sulfonamides</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Antibiotic Resistance and Stewardship</h1>
        
        <p>The emergence of <b>antibiotic resistance</b> poses one of the most serious threats to global health. Resistance occurs when bacteria evolve mechanisms to withstand antibiotics that would normally kill them or inhibit their growth. This natural evolutionary process has been dramatically accelerated by misuse and overuse of antibiotics in human medicine and agriculture.</p>
        
        <h2>Mechanisms of Resistance</h2>
        <p>Bacteria employ several strategies to resist antibiotics:</p>
        <ol>
            <li><b>Enzymatic inactivation</b>: Production of enzymes that modify or destroy antibiotics (e.g., β-lactamases that hydrolyze β-lactam antibiotics)</li>
            <li><b>Target modification</b>: Alteration of antibiotic binding sites (e.g., penicillin-binding protein changes in MRSA)</li>
            <li><b>Efflux pumps</b>: Active transport of antibiotics out of the bacterial cell</li>
            <li><b>Reduced permeability</b>: Decreased antibiotic uptake through cell wall/membrane changes</li>
            <li><b>Bypass pathways</b>: Development of alternative metabolic pathways</li>
        </ol>
        
        <h2>Antibiotic Stewardship</h2>
        <p>Antibiotic stewardship programs aim to optimize antibiotic use to improve patient outcomes while minimizing unintended consequences. Key principles include:</p>
        <ol>
            <li><b>Right drug</b>: Selecting the most targeted, narrow-spectrum antibiotic effective against the likely pathogen</li>
            <li><b>Right dose</b>: Using pharmacokinetic/pharmacodynamic principles to determine optimal dosing</li>
            <li><b>Right duration</b>: Treating for the shortest effective duration</li>
            <li><b>De-escalation</b>: Transitioning from broad-spectrum to narrow-spectrum therapy when possible</li>
            <li><b>Prevention</b>: Emphasizing infection prevention measures to reduce antibiotic need</li>
        </ol>
        
        <div class="mnemonic">
            <b>Mnemonic: "MEDIC" for antibiotic stewardship principles</b><br>
            <b>M</b>icrobiology guidance<br>
            <b>E</b>mpiric therapy when needed, but tailor when possible<br>
            <b>D</b>ose optimization<br>
            <b>I</b>nfection prevention<br>
            <b>C</b>ommunication and education
        </div>
    </div>

    <div class="question-card">
        <h1>Question 3</h1>
        <p>Which of the following is NOT a mechanism of antibiotic resistance?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Production of β-lactamase enzymes</li>
            <li data-answer="wrong">Modification of ribosomal binding sites</li>
            <li data-answer="correct">Increased antibody production by bacteria</li>
            <li data-answer="wrong">Upregulation of efflux pumps</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 4</h1>
        <p>Which principle of antibiotic stewardship is demonstrated when switching from piperacillin-tazobactam to ampicillin once culture results show ampicillin-sensitive E. coli?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Right dose</li>
            <li data-answer="correct">De-escalation</li>
            <li data-answer="wrong">Infection prevention</li>
            <li data-answer="wrong">Microbiology guidance</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Beta-Lactam Antibiotics</h1>
        
        <p><b>β-lactam antibiotics</b> are the most commonly prescribed antibiotic class, characterized by their β-lactam ring structure. This four-membered ring binds to and inhibits penicillin-binding proteins (PBPs), enzymes critical for bacterial cell wall synthesis. Inhibition leads to defective cell wall formation and bacterial lysis.</p>
        
        <h2>Major Subclasses</h2>
        <ol>
            <li><b>Penicillins</b>: Natural (penicillin G, V), anti-staphylococcal (nafcillin, oxacillin), aminopenicillins (ampicillin, amoxicillin), antipseudomonal (piperacillin)</li>
            <li><b>Cephalosporins</b>: Divided into generations based on spectrum (1st: cefazolin; 3rd: ceftriaxone; 5th: ceftaroline)</li>
            <li><b>Carbapenems</b>: Broadest spectrum β-lactams (imipenem, meropenem, ertapenem)</li>
            <li><b>Monobactams</b> (aztreonam): Primarily active against Gram-negatives</li>
            <li><b>β-lactamase inhibitor combinations</b>: Clavulanate, sulbactam, tazobactam paired with various β-lactams</li>
        </ol>
        
        <h2>Clinical Considerations</h2>
        <p><b>Spectrum of activity</b> varies significantly among subclasses. Natural penicillins primarily target Gram-positives and some anaerobes, while later-generation cephalosporins and carbapenems cover many Gram-negatives. <b>Resistance</b> commonly occurs via β-lactamase production or PBP modification (e.g., MRSA).</p>
        
        <p><b>Adverse effects</b> include hypersensitivity reactions (ranging from rash to anaphylaxis), neurotoxicity (especially with high doses or renal impairment), and Clostridioides difficile infection. Cross-reactivity between penicillins and cephalosporins occurs in about 1-3% of patients with penicillin allergy.</p>
        
        <div class="mnemonic">
            <b>Mnemonic: "Very Finely Proficient At Killing" for penicillin generations</b><br>
            <b>V</b> - Penicillin V (natural)<br>
            <b>F</b> - Flucloxacillin (anti-staph)<br>
            <b>P</b> - Piperacillin (anti-pseudomonal)<br>
            <b>A</b> - Amoxicillin (aminopenicillin)<br>
            <b>K</b> - Combinations (e.g., co-amoxiclav)
        </div>
    </div>

    <div class="question-card">
        <h1>Question 5</h1>
        <p>A patient with a history of anaphylaxis to penicillin requires treatment for Pseudomonas aeruginosa bacteremia. Which β-lactam could be safely used?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Piperacillin-tazobactam</li>
            <li data-answer="wrong">Ceftazidime</li>
            <li data-answer="correct">Aztreonam</li>
            <li data-answer="wrong">Amoxicillin-clavulanate</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 6</h1>
        <p>Which mechanism best explains resistance to β-lactams in MRSA?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Production of extended-spectrum β-lactamases</li>
            <li data-answer="correct">Alteration of penicillin-binding proteins</li>
            <li data-answer="wrong">Development of efflux pumps</li>
            <li data-answer="wrong">Mutation of porin channels</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Aminoglycosides</h1>
        
        <p><b>Aminoglycosides</b> are potent bactericidal antibiotics that bind to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis. Their concentration-dependent killing makes them particularly effective when high peak concentrations are achieved.</p>
        
        <h2>Key Agents</h2>
        <p>Common aminoglycosides include gentamicin, tobramycin, amikacin, and streptomycin. Each has slightly different spectra:</p>
        <ol>
            <li><b>Gentamicin</b>: Most commonly used, active against many Gram-negatives and some Gram-positives (e.g., synergistic with β-lactams for enterococcal endocarditis)</li>
            <li><b>Tobramycin</b>: Slightly more active against Pseudomonas than gentamicin</li>
            <li><b>Amikacin</b>: Most resistant to aminoglycoside-modifying enzymes, often used for resistant Gram-negatives</li>
        </ol>
        
        <h2>Clinical Use</h2>
        <p>Aminoglycosides are primarily used for:</p>
        <ol>
            <li>Severe Gram-negative infections (often combined with β-lactams for synergy)</li>
            <li>Empiric treatment of sepsis</li>
            <li>Combination therapy for endocarditis (with cell-wall active agents)</li>
            <li>Topical formulations for ocular and skin infections</li>
        </ol>
        
        <h2>Toxicity</h2>
        <p>The major limitations are nephrotoxicity and ototoxicity (both vestibular and cochlear). Risk factors include prolonged use, high trough levels, concomitant nephrotoxins, and pre-existing renal impairment. Monitoring includes:</p>
        <ol>
            <li>Serum drug levels (peak and trough)</li>
            <li>Renal function tests</li>
            <li>Baseline and serial audiometry for prolonged courses</li>
        </ol>
        
        <div class="mnemonic">
            <b>Mnemonic: "A Mean Ototoxic Nephrotoxic" for aminoglycoside toxicities</b><br>
            <b>A</b>minoglycosides cause<br>
            <b>M</b>yasthenia gravis exacerbation (rare)<br>
            <b>O</b>totoxicity<br>
            <b>N</b>ephrotoxicity
        </div>
    </div>

    <div class="question-card">
        <h1>Question 7</h1>
        <p>Which monitoring is most critical when using aminoglycosides for more than 3 days?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Complete blood count</li>
            <li data-answer="wrong">Liver function tests</li>
            <li data-answer="correct">Renal function and drug levels</li>
            <li data-answer="wrong">Coagulation studies</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 8</h1>
        <p>Why are aminoglycosides typically dosed once daily?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">To reduce gastrointestinal side effects</li>
            <li data-answer="wrong">Because they have a very short half-life</li>
            <li data-answer="correct">To maximize concentration-dependent killing while minimizing toxicity</li>
            <li data-answer="wrong">Because they are bacteriostatic at lower doses</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Tetracyclines</h1>
        
        <p><b>Tetracyclines</b> are broad-spectrum bacteriostatic antibiotics that reversibly bind to the 30S ribosomal subunit, blocking tRNA attachment and inhibiting protein synthesis. The class includes natural compounds (tetracycline, chlortetracycline) and semi-synthetic derivatives (doxycycline, minocycline, tigecycline).</p>
        
        <h2>Spectrum and Uses</h2>
        <p>Tetracyclines have activity against:</p>
        <ol>
            <li>Atypical bacteria (Mycoplasma, Chlamydia, Rickettsia)</li>
            <li>Some Gram-positives and Gram-negatives</li>
            <li>Spirochetes (Borrelia burgdorferi causing Lyme disease)</li>
            <li>Certain parasites (e.g., malaria)</li>
        </ol>
        
        <p>Key clinical uses include:</p>
        <ol>
            <li>Community-acquired pneumonia (atypical coverage)</li>
            <li>Lyme disease</li>
            <li>Acne vulgaris (long-term low-dose doxycycline)</li>
            <li>Rickettsial infections (e.g., Rocky Mountain spotted fever)</li>
            <li>Brucellosis (with rifampin or streptomycin)</li>
        </ol>
        
        <h2>Pharmacokinetics</h2>
        <p>Doxycycline has excellent oral bioavailability and is preferred for most indications. Tigecycline (a glycylcycline) has expanded Gram-positive coverage but carries a black box warning for increased mortality in serious infections. Tetracyclines chelate divalent cations (Ca²⁺, Mg²⁺, Al³⁺, Fe²⁺), requiring separation from antacids, dairy, and supplements by 2-3 hours.</p>
        
        <h2>Adverse Effects</h2>
        <ol>
            <li><b>Photosensitivity</b> (especially doxycycline)</li>
            <li><b>Tooth discoloration</b> and enamel hypoplasia (contraindicated in pregnancy and children <8 years)</li>
            <li><b>Esophageal irritation</b> (take with ample water, avoid bedtime dosing)</li>
            <li><b>Benign intracranial hypertension</b> (rare)</li>
            <li><b>Vestibular toxicity</b> (minocycline)</li>
        </ol>
        
        <div class="mnemonic">
            <b>Mnemonic: "TETRACYCLINE" for key facts</b><br>
            <b>T</b>ooth discoloration<br>
            <b>E</b>sophageal irritation<br>
            <b>T</b>ake without dairy<br>
            <b>R</b>ickettsial infections<br>
            <b>A</b>typical coverage<br>
            <b>C</b>helates metals<br>
            <b>Y</b>ellow teeth in kids<br>
            <b>C</b>ontraindicated in pregnancy<br>
            <b>L</b>yme disease treatment<br>
            <b>I</b>ntracranial hypertension risk<br>
            <b>N</b>ot for children under 8<br>
            <b>E</b>xpired tetracyclines can cause Fanconi syndrome
        </div>
    </div>

    <div class="question-card">
        <h1>Question 9</h1>
        <p>A 25-year-old woman presents with Rocky Mountain spotted fever. Which tetracycline is preferred?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Tetracycline</li>
            <li data-answer="correct">Doxycycline</li>
            <li data-answer="wrong">Minocycline</li>
            <li data-answer="wrong">Tigecycline</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 10</h1>
        <p>Why are tetracyclines contraindicated in pregnancy?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Risk of miscarriage</li>
            <li data-answer="wrong">Increased risk of preeclampsia</li>
            <li data-answer="correct">Potential for fetal tooth discoloration and bone growth inhibition</li>
            <li data-answer="wrong">High risk of anaphylaxis in pregnant women</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Macrolides</h1>
        
        <p><b>Macrolides</b> are bacteriostatic antibiotics that bind to the 50S ribosomal subunit, blocking peptide chain elongation. The class includes erythromycin (original agent), clarithromycin, and azithromycin (azalide subclass).</p>
        
        <h2>Spectrum and Clinical Use</h2>
        <p>Macrolides are particularly valuable for:</p>
        <ol>
            <li><b>Atypical pneumonia</b> (Mycoplasma, Chlamydophila, Legionella)</li>
            <li><b>Community-acquired pneumonia</b> (Streptococcus pneumoniae, though resistance is increasing)</li>
            <li><b>Pertussis</b> (erythromycin)</li>
            <li><b>Mycobacterial infections</b> (clarithromycin for MAC)</li>
            <li><b>STIs</b> (azithromycin for chlamydia)</li>
            <li><b>Gastric motility</b> (erythromycin as a motilin agonist)</li>
        </ol>
        
        <h2>Pharmacokinetics</h2>
        <p>Key differences exist among agents:</p>
        <ol>
            <li><b>Azithromycin</b>: Long tissue half-life allowing short-course therapy (e.g., 5-day or even single-dose regimens)</li>
            <li><b>Clarithromycin</b>: Metabolized by CYP3A4, with an active metabolite</li>
            <li><b>Erythromycin</b>: Short half-life requiring QID dosing, potent CYP3A4 inhibitor</li>
        </ol>
        
        <h2>Adverse Effects</h2>
        <ol>
            <li><b>GI upset</b> (especially erythromycin - stimulates motilin receptors)</li>
            <li><b>QT prolongation</b> (risk of torsades de pointes, especially with azithromycin in high-risk patients)</li>
            <li><b>Hepatotoxicity</b> (cholestatic hepatitis with erythromycin estolate)</li>
            <li><b>Drug interactions</b> (erythromycin and clarithromycin are strong CYP3A4 inhibitors)</li>
            <li><b>Ototoxicity</b> (high doses, especially in renal impairment)</li>
        </ol>
        
        <div class="mnemonic">
            <b>Mnemonic: "MACrolides" for key indications</b><br>
            <b>M</b>ycoplasma<br>
            <b>A</b>typical pneumonia<br>
            <b>C</b>hlamydia<br>
            Also: Campylobacter, Community-acquired pneumonia, COPD exacerbations
        </div>
    </div>

    <div class="question-card">
        <h1>Question 11</h1>
        <p>Which macrolide is most likely to cause significant QT prolongation when prescribed with amiodarone?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Erythromycin</li>
            <li data-answer="correct">Azithromycin</li>
            <li data-answer="wrong">Clarithromycin</li>
            <li data-answer="wrong">All carry equal risk</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 12</h1>
        <p>A patient on simvastatin develops rhabdomyolysis after starting a new antibiotic. Which macrolide most likely caused this interaction?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Azithromycin</li>
            <li data-answer="correct">Clarithromycin</li>
            <li data-answer="wrong">Both carry equal risk</li>
            <li data-answer="wrong">Neither would cause this interaction</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Fluoroquinolones</h1>
        
        <p><b>Fluoroquinolones</b> are broad-spectrum bactericidal antibiotics that inhibit bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription. The fluorine atom at position 6 distinguishes fluoroquinolones from earlier quinolones (e.g., nalidixic acid).</p>
        
        <h2>Generations and Spectrum</h2>
        <p>Fluoroquinolones are classified by generation:</p>
        <ol>
            <li><b>1st</b>: Narrow Gram-negative (norfloxacin, ciprofloxacin)</li>
            <li><b>2nd</b>: Expanded Gram-positive (levofloxacin, ofloxacin)</li>
            <li><b>3rd</b>: Respiratory fluoroquinolones with enhanced Gram-positive and atypical coverage (moxifloxacin, gemifloxacin)</li>
            <li><b>4th</b>: Broadest spectrum including anaerobes (delafloxacin)</li>
        </ol>
        
        <h2>Clinical Uses</h2>
        <p>Fluoroquinolones are used for:</p>
        <ol>
            <li><b>UTIs</b> (ciprofloxacin, levofloxacin)</li>
            <li><b>Intra-abdominal infections</b> (combined with metronidazole)</li>
            <li><b>Respiratory infections</b> (community-acquired pneumonia, exacerbations of COPD)</li>
            <li><b>Bone/joint infections</b> (especially Gram-negative)</li>
            <li><b>Anthrax</b> (ciprofloxacin)</li>
        </ol>
        
        <h2>Adverse Effects and Black Box Warnings</h2>
        <p>FDA warnings limit fluoroquinolone use due to:</p>
        <ol>
            <li><b>Tendon rupture</b> (risk increases with age >60, corticosteroids, renal disease)</li>
            <li><b>Peripheral neuropathy</b> (may be irreversible)</li>
            <li><b>CNS effects</b> (insomnia, dizziness, rarely seizures)</li>
            <li><b>QT prolongation</b> (especially moxifloxacin)</li>
            <li><b>Hypoglycemia</b> (enhanced insulin secretion, particularly with gatifloxacin - now withdrawn)</li>
            <li><b>Aortic dissection</b> (recent association with cumulative use)</li>
        </ol>
        
        <div class="mnemonic">
            <b>Mnemonic: "QUINOLONE" for toxicities</b><br>
            <b>Q</b>T prolongation<br>
            <b>U</b>pset GI<br>
            <b>I</b>nsomnia/CNS effects<br>
            <b>N</b>europathy<br>
            <b>O</b>ff tendons (rupture risk)<br>
            <b>L</b>ow glucose (hypoglycemia)<br>
            <b>O</b>ral only for some (IV available for most)<br>
            <b>N</b>ot in kids (cartilage damage)<br>
            <b>E</b>xacerbates myasthenia gravis
        </div>
    </div>

    <div class="question-card">
        <h1>Question 13</h1>
        <p>Which fluoroquinolone is most likely to cause QT prolongation?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Ciprofloxacin</li>
            <li data-answer="correct">Moxifloxacin</li>
            <li data-answer="wrong">Levofloxacin</li>
            <li data-answer="wrong">Norfloxacin</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 14</h1>
        <p>A 65-year-old man on prednisone develops acute Achilles tendon pain after starting an antibiotic for prostatitis. Which antibiotic most likely caused this?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Amoxicillin</li>
            <li data-answer="wrong">Doxycycline</li>
            <li data-answer="correct">Ciprofloxacin</li>
            <li data-answer="wrong">Azithromycin</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Rifamycins (Rifampin/Rifabutin)</h1>
        
        <p><b>Rifamycins</b> are bactericidal antibiotics that inhibit DNA-dependent RNA polymerase, blocking transcription. Rifampin is the prototypical agent, with rifabutin having similar activity but fewer drug interactions.</p>
        
        <h2>Spectrum and Uses</h2>
        <p>Rifamycins have unparalleled activity against:</p>
        <ol>
            <li><b>Mycobacterium tuberculosis</b> (first-line TB therapy)</li>
            <li><b>Mycobacterium leprae</b> (leprosy)</li>
            <li><b>Staphylococcus aureus</b> (used for MSSA/MRSA in combination therapy)</li>
            <li><b>Neisseria meningitidis</b> (prophylaxis)</li>
        </ol>
        
        <p>Unique uses include:</p>
        <ol>
            <li><b>Latent TB treatment</b> (short-course rifampin or rifapentine)</li>
            <li><b>Prosthetic joint infection</b> (biofilm-active in combination)</li>
            <li><b>Brucellosis</b> (with doxycycline)</li>
            <li><b>MRSA bacteremia</b> (adjunct to vancomycin/daptomycin)</li>
        </ol>
        
        <h2>Pharmacokinetics</h2>
        <p>Rifampin is a <b>potent inducer of CYP450 enzymes</b> (particularly 3A4), accelerating metabolism of many drugs (e.g., warfarin, oral contraceptives, antiretrovirals). It turns body fluids orange-red (harmless but alarming). Rifabutin causes less enzyme induction and is preferred in HIV patients on antiretrovirals.</p>
        
        <h2>Adverse Effects</h2>
        <ol>
            <li><b>Hepatotoxicity</b> (monitor LFTs, especially with pre-existing liver disease)</li>
            <li><b>Drug interactions</b> (must review all concomitant medications)</li>
            <li><b>Flu-like syndrome</b> (with intermittent dosing)</li>
            <li><b>Thrombocytopenia</b> (rare)</li>
            <li><b>Orange discoloration</b> of urine, tears, sweat</li>
        </ol>
        
        <div class="mnemonic">
            <b>Mnemonic: "RIFAMPIN" for key facts</b><br>
            <b>R</b>ed/orange body fluids<br>
            <b>I</b>nduces CYP450<br>
            <b>F</b>irst-line for TB<br>
            <b>A</b>djunct for staph<br>
            <b>M</b>onitor LFTs<br>
            <b>P</b>rophylaxis for meningococcus<br>
            <b>I</b>nteractions galore<br>
            <b>N</b>ever use as monotherapy (rapid resistance)
        </div>
    </div>

    <div class="question-card">
        <h1>Question 15</h1>
        <p>A patient on warfarin develops subtherapeutic INRs after starting a new medication for latent TB. Which drug most likely caused this interaction?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Isoniazid</li>
            <li data-answer="correct">Rifampin</li>
            <li data-answer="wrong">Pyrazinamide</li>
            <li data-answer="wrong">Ethambutol</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 16</h1>
        <p>Which rifamycin is preferred for a patient on ritonavir-boosted HIV therapy who needs treatment for MAC?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Rifampin</li>
            <li data-answer="correct">Rifabutin</li>
            <li data-answer="wrong">Either could be used with dose adjustment</li>
            <li data-answer="wrong">Neither should be used</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Sulfonamides and Trimethoprim</h1>
        
        <p><b>Sulfonamides</b> and <b>trimethoprim</b> are synthetic antibiotics that inhibit sequential steps in folate synthesis - sulfonamides block dihydropteroate synthase (DHPS), while trimethoprim inhibits dihydrofolate reductase (DHFR). Used alone, each is bacteriostatic; combined (as co-trimoxazole), they become bactericidal.</p>
        
        <h2>Spectrum and Uses</h2>
        <p>Co-trimoxazole (TMP-SMX) has broad activity against:</p>
        <ol>
            <li><b>Gram-positives</b> (including some MRSA)</li>
            <li><b>Gram-negatives</b> (E. coli, Klebsiella, Salmonella, Shigella)</li>
            <li><b>Pneumocystis jirovecii</b> (treatment and prophylaxis)</li>
            <li><b>Toxoplasma gondii</b> (prophylaxis in AIDS)</li>
            <li><b>Nocardia</b></li>
        </ol>
        
        <p>Key indications include:</p>
        <ol>
            <li><b>UTIs</b> (though resistance is increasing)</li>
            <li><b>PCP pneumonia</b> (high-dose IV for moderate-severe)</li>
            <li><b>MRSA skin infections</b></li>
            <li><b>Traveler's diarrhea</b> (in areas with susceptible organisms)</li>
            <li><b>Prophylaxis</b> in immunocompromised hosts</li>
        </ol>
        
        <h2>Adverse Effects</h2>
        <ol>
            <li><b>Hypersensitivity reactions</b> (rash, Stevens-Johnson syndrome - higher risk in HIV)</li>
            <li><b>Hematologic toxicity</b> (megaloblastic anemia, leukopenia - especially in folate deficiency)</li>
            <li><b>Hyperkalemia</b> (trimethoprim blocks renal epithelial sodium channels, similar to amiloride)</li>
            <li><b>Renal toxicity</b> (crystalluria with sulfonamides, especially in acidic urine)</li>
            <li><b>Photosensitivity</b></li>
            <li><b>Drug interactions</b> (sulfonamides potentiate warfarin, sulfonylureas)</li>
        </ol>

        <div class="mnemonic">
            <b>Mnemonic: "SULFA" for key toxicities</b><br>
            <b>S</b>tevens-Johnson syndrome<br>
            <b>U</b>rinary crystals (hydrate well)<br>
            <b>L</b>ow platelets (thrombocytopenia)<br>
            <b>F</b>olate deficiency exacerbation<br>
            <b>A</b>llergy common
        </div>
    </div>

    <div class="question-card">
        <h1>Question 17</h1>
        <p>A patient with AIDS develops hyperkalemia after starting high-dose TMP-SMX for PCP pneumonia. Which component causes this effect?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Sulfamethoxazole</li>
            <li data-answer="correct">Trimethoprim</li>
            <li data-answer="wrong">Both components contribute equally</li>
            <li data-answer="wrong">Neither - this must be from another cause</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 18</h1>
        <p>Which patient is at highest risk for severe hypersensitivity to TMP-SMX?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">A 25-year-old with uncomplicated UTI</li>
            <li data-answer="wrong">A 50-year-old with COPD</li>
            <li data-answer="correct">A 35-year-old with untreated HIV and CD4 count of 50</li>
            <li data-answer="wrong">A 60-year-old on warfarin</li>
        </ul>
    </div>

    <div class="placeholder" id="empty">Test</div>

</div>